RxDoctor Payments Data

Katie Casey, NP

Family · Festus, MONPI 1225452501

Payments from drug & device makers

$7,059in general payments, 2019–2025

Across 376 payments — averaging $18.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$1K
  • Novo Nordisk$1K
  • Abbott$677
  • AstraZeneca$611
  • Medtronic$397
  • AbbVie$318
  • plus $3K from 37 others

What the payments were for

  • Food & beverage$6,90398%
  • Education$971%
  • Gifts$591%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,059 in reported general payments places this provider in the 95th percentile of 3,812 family providers in Missouri.

See all family providers in Missouri

Medicare billing

Part B allowed, 2024
$30,676
Medicare patients
124
Services billed
620

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide362$567,013
JardianceEmpagliflozin265$316,438
MounjaroTirzepatide211$312,672
TrulicityDulaglutide113$184,423
Tresiba Flextouch U-200Insulin Degludec113$108,311
FarxigaDapagliflozin Propanediol79$97,280
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog80$90,913
Tresiba Flextouch U-100Insulin Degludec101$69,630
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog99$63,869
Soliqua 100-33Insulin Glargine/Lixisenatide46$55,850
Fiasp FlextouchInsulin Aspart (Niacinamide)45$39,827
RybelsusSemaglutide19$39,205
Omnipod Dash Pods (Gen 4)Insulin Pump Cart,cont Inf,bt28$34,975
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/716$34,170
Humalog Kwikpen U-100Insulin Lispro92$28,933

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$1,259$606,218381 claims
Lilly USA, LLCMounjaro, Trulicity, Humalog, Insulin Lispro$1,275$506,634375 claims
Boehringer IngelheimJardiance, Synjardy Xr$265$345,145282 claims
AstraZenecaFarxiga$611$97,28079 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$104$55,85046 claims
MerckJanuvia$62$15,81314 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,812 family providers in Missouri.

Other family in Festus

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →